Slowing and possible prevention of disease progression

There is an urgent need for more manageable surrogate markers that could identify candidate treatments that might slow disease progression.1

While FEV1 decline has to date been regarded as the gold standard of COPD progression, different measures are likely to provide a more specific assessment of disease activity and progression within clinical subtypes of COPD. In the past, only the therapeutic intervention of smoking cessation  has been demonstrated to alter the natural history of COPD.2 However, studies have shown that a combination of an LABA and ICS may slow the decline in lung function in COPD patients.3

References

  1. Cazzola M, MacNee W, Martinez FJ, et al. Outcomes for COPD pharmacological trials: from lung function to biomarkers. Eur Respir J 2008;31:416-69.
  2. Anthonisen NR, Connett JE, Kiley JP, et al. Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1. The Lung Health Study. JAMA 1994;272:1497-505.
  3. Celli BR, Thomas NE, Anderson JA, et al. Effect of pharmacotherapy on rate of decline of lung function inc chronic obstructive pulmonary disease: results from the TORCH study. Am J Respir Crit Care Med 2008;178:332-8.

Inflammation in COPD

Learn more about the central role of inflammation in COPD.Go

Contact us

Need more information? Contact

Find this page interesting?

Maybe a colleague will too? Share page

Access

The information contained in this site is for healthcare professionals only. Click ok if you are a healthcare professional.

Ok
Close